We support and engage patients and medical professionals to advance knowledge and improve care for patients and practitioners facing red blood cell questions and conditions.  

Red blood cells that have been grown in a laboratory have now been transfused into another person in a world first clinical trial. The manufactured blood cells were grown from stem cells from donors. The red cells were then transfused into volunteers in the RESTORE randomized controlled clinical trial.

Globally, this is the first-time red blood cells that have been grown in a laboratory have been given to a person as part of a trial into blood transfusion. 

If proved safe and effective, manufactured blood cells could in time Revolutionize treatments for people with blood disorders such as sickle cell and rare blood types. It can be difficult to find enough well-matched donated blood for some people with these disorders.

Some clinical trials are joint research initiatives by NHS Blood and Transplant (NHSBT) and the University of Bristol, working with the University of Cambridge, Guy’s and St Thomas’ NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Cambridge Clinical Research Facility, and Cambridge University Hospitals NHS Foundation Trust, funded by a NIHR grant. 

One clinical trial is studying the lifespan of the lab grown cells compared with infusions of standard red blood cells from the same donor. The lab-grown blood cells are all fresh, so the trial team expect them to perform better than a similar transfusion of standard donated red cells, which contains cells of varying ages.

Additionally, if manufactured cells last longer in the body, patients who regularly need blood may not need transfusions as often. Significantly, such may reduce iron overload from frequent blood transfusions, which can potentially lead to very serious complications.

The trial is the first step towards making lab grown red blood cells available as a future clinical product. For the foreseeable future, manufactured cells could only be used for a very small number of patients with very complex transfusions needs. NHSBT continues to rely on the generosity of donors. (2)

Two people have so far been transfused with the lab grown red cells. They were closely monitored and no untoward side effects were reported. They are well and healthy. The identities of participants infused so far are not currently being released, to help keep the trial ‘blinded’.

DONOR RECRUITMENT 

Donors have been recruited from NHSBT’s blood donor base. They donated blood to the trial and stem cells were separated out from their blood. These stem cells were then grown to produce red blood cells in a laboratory at NHSBT’s Advanced Therapies Unit. The recipients of the blood were recruited from healthy members of the NIHR BioResource.

A minimum number of participants receives transfusions at least four months apart, one of standard donated red cells and one of lab grown red cells, to determine if the young red blood cells produced in the laboratory may last longer than cells produced in the body.

Further trials are needed before clinical use, but this research marks a significant step in using lab grown red blood cells to improve treatment for patients with rare blood types or people with complex transfusion needs.

Professor Ashley Toye, Professor of Cell Biology at the University of Bristol and Director of the NIHR Blood and Transplant Unit in red cell products, said: “This challenging and exciting trial is a huge stepping stone for manufacturing blood from stem cells. This is the first-time lab grown blood from an allogeneic donor has been transfused and we are excited to see how well the cells perform at the end of the clinical trial.”

Chief Investigator Professor Cedric Ghevaert, Professor in Transfusion Medicine and Consultant Haematologist the University of Cambridge and NHSBT, said: “We hope our lab grown red blood cells will last longer than those that come from blood donors. If our trial, the first such in the world, is successful, it will mean that patients who currently require regular long-term blood transfusions will need fewer transfusions in future, helping transform their care.”

Dr Rebecca Cardigan, Head of Component Development at NHSBT and Affiliated Lecturer at the University of Cambridge said: “It’s really fantastic that we are now able to grow enough red cells to medical grade to allow this trial to commence, we are really looking forward to seeing the results and whether they perform better than standard red cells” according to 

 John James OBE, Chief Executive of the Sickle Cell Society and Farrukh Shah, Medical Director of Transfusion for NHS Blood and Transplant, and Neil O’Brien, Minister of State for Health.

ABOUT RED BLOOD CELL VOLUNTEER DONORS

• Red blood cells are grown at NHSBT’s Advanced Therapies Unit in the Cellular and Molecular Therapies function in Filton from blood donors who have agreed to take part in the study. The cells are labelled with a tracer element by a Radiopharmacy Unit so they can be tracked through the recipient’s body when they are transfused. 
  Recipient volunteers are recruited through the NIHR BioResource and study clinical team and receive their infusions in the NIHR Cambridge Clinical Research Facility. Cambridge University Hospitals NHS Foundation Trust provides pharmacy, laboratory, and research support.